Polyinosine-polycytidylic acid (pIC) is a synthetic dsRNA that acts as an immune agonist of TLR3 and RLR to activate dendritic and NK cells that can kill tumor cells. pIC can also trigger apoptosis in pancreatic ductal adenocarcinoma cells but its mechanism of action is obscure. In this study, we investigated the potential therapeutic activity of a formulation of pIC with 
high fatality of pancreatic cancer is attributed to failure to diagnosis the disease early (before it has metastasized to other organs) and resistance to current therapies (8) .
Surgical removal of pancreatic cancer can cure a small percentage of patients, but survival rates after pancreatectomy are extremely low (9) . Chemotherapy or radiation employed alone or in combination, is only palliative and provides little or no benefit for patients suffering from advanced pancreatic cancer (10) . The current FDA-approved cytotoxic treatment for advanced pancreatic cancer remains gemcitabine (11). Even though gemcitabine is well tolerated, its efficacy is marginal with a median survival of 6 months. The combination of 5-fluorouracil, leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) showed superiority over single agent gemcitabine in patients with metastatic pancreatic cancer (from 6.8 months with gemcitabine to 11.1 months with FOLFIRINOX) (11). However, FOLFIRINOX had greater toxicity including grade 3 or 4 neutropenia, febrile neutropenia, thrombocytopenia, diarrhea, neuropathy, vomiting, and fatigue (12) . Considering its aggressiveness and lack of currently effective therapies, a dire need exists for newer strategies to treat pancreatic cancer. Characterization of new activated oncogenic signaling pathways, defining molecular pathways involved in resistance and/or targeting those genes involved in these pathways in pancreatic cancer cells may lead to more effective therapeutic strategies for pancreatic cancer treatment (13) (14) (15) .
The immune system plays a pivotal role in pathophysiology of pancreatitis and PDAC development (16) . Eukaryotic cells contain pattern recognition receptors that detect viral/bacterial nucleic acids activating antiviral immune responses (17, 18) . Toll like receptors (TLRs) function as pattern recognition receptors and primary sensors of bacteria and viruses (19) .
Activation of TLRs decreases expression of co-stimulatory molecules on tumor cells, immunosuppressive functions of regulatory T cells, and production of anti-proliferative cytokines (20) . TLR agonists activate immune responses promoting tolerance to tumor antigens and serve as adjuvants in cancer immunotherapy clinical trials (21) .
[pIC], is a synthetic dsRNA directly activating dendritic cells and triggering NK cells to kill tumor cells (22) .
[pIC] mimics viral RNA serving as an agonist of TLR3 and RLRs, and has been extensively used as an immune adjuvant in clinical trials (23) . Although [pIC] initiates apoptosis in several cancers its mechanism of action in human PDAC is not clear. [pIC] induces high levels of type I interferons and activates several nuclear and cytoplasmic enzyme systems including OAS (oligoadenylate synthetase), the dsRNA-dependent protein kinase [PKR] , RIG-I Helicase, and MDA-5 [melanoma differentiation associated gene -5] that are involved in antiviral and antitumor host defenses (19, 23) . Polyethylenimine (PEI) is a promising reagent increasing transfection efficiency of nucleic acids including DNA, siRNA or RNA when administered in vivo (24) . Complexing Jet-PEI with several DNA or other vectors leads to a significant increase in transfection efficiency (25) 
Plasmid transfection
Plasmid transfection experiments used FuGene HD transfection reagent using the manufacturer's protocol (Roche, Indianapolis, IN) and described in supplemental methods.
Cell proliferation assays (MTT assay)
Cell growth rate was determined using a modified MTT assay as described (28) .
Colony formation assays
Cells were either mock-treated or exposed to [ 
LC3 assay
We used a previous protocol with minor changes (29) and described in supplemental methods in detail. 
Terminal deoxy nucleotidyl transferase-mediated nick labeling (TUNEL) assay

Western blotting
Western blotting analysis was performed as described (28, 30) .
In vivo studies 
Quasi-orthotopic tumor studies
MIA PaCa-2-luc cells (5 X 10 6 ) were injected intra-peritoneally into nude mice.
Bioluminescence imaging (BLI) was performed every week after tumor cell implantation. After 2-weeks of cell implantation, mice were divided into two groups with 10 mice per group. One group was used as tumor growth control, without any treatment, and the other group was injected twice weekly with [pIC] PEI (1 mg/Kg) intra-peritoneally (total of 4 doses). Control and treated mice were observed for tumor progression using BLI. All mice were sacrificed once mice either lost body weight or developed impaired mobility.
Statistical analysis
All data are presented as mean ± standard deviation (S.D.) of at least three independent experiments, each performed at least in triplicate. One-way analysis of variance (ANOVA) combined with the Tukey post hoc test of means was used for multiple comparisons. Statistical differences are presented at probability levels of p < 0.05, p < 0.01 and p < 0.001. (25) (26) (27) 31) .
Results
However, the precise mechanism(s) underlying these effects are not fully understood. The effect of [pIC] PEI on normal and PDAC cell growth was evaluated using MTT assays (Fig. 1) .
Treatment altering LT-2 clonogenic ability (~9% reduction) ( Fig 1C) .
[pIC] PEI induces autophagy in PDAC cells
Previous studies demonstrated that treatment of human melanoma [25] (Fig. 2C ).
[pIC] PEI selectively induces apoptosis in PDAC cells [pIC]
PEI induces MDA-5 and TLR-3 in melanoma cells, which was critical for induction of toxic autophagy (25) . In breast cancer cells, knockdown of MDA-5 significantly restored viability after transfection with [pIC], whereas knockdown of TLR-3 did not protect cells (26) .
[pIC] PEI transfection in PDAC increased RIG-I, MDA-5 and NOXA as compared to mock controls ( Fig. 4) Fig 2) .
[pIC] PEI triggers X-linked inhibitor of apoptosis protein (XIAP) and survivin degradation in PDAC cells
Overexpression of the Bcl-2 family of anti-apoptotic proteins is a frequent occurrence in PDAC and serves as a barrier to effective treatment (3, 4) . XIAP overexpression is frequently observed in PDAC and XIAP degradation or inhibition can sensitize PDAC to apoptosis (12) . PEI -induced cell death (Fig. 5C, Supplementary Fig. 5B ) As, XIAP and survivin play significant roles in PDAC development, we determined the effects of 
[pIC] PEI mediates mTOR-PKC-ε-mediated AKT regulation in PDAC cells
Previous studies show that mTOR can regulate AKT in several cancers (34) . AKT has also been reported to be a downstream effector of PKC-ε in ethanol-induced cardioprotection, and inhibition of PKC-ε prevented the increase in AKT activity (35) . To define the effects of [pIC]
PEI on mTOR-PKC-ε link, we performed western blotting analysis for mTOR and PKC-ε.
[pIC]
PEI transfection in PDAC decreased mTOR protein levels and mTOR activation in a dose-dependent manner ( Supplementary Fig 7) . We also showed that [pIC] PEI treatment of PDAC decreased PKC-ε in a dose-dependent manner ( Figure 6 and Supplementary Fig 7) . Our results emphasize that PKC-ε and AKT act in a positive feed back loop, since AKT overexpression led to an increase in PKC-ε in PDAC cells ( Figure 6D ). These results suggest a potential role of mTOR- 
PKC-ε in regulating AKT following [pIC]
PEI treatment, which warrant further future investigation. (Fig. 7D) . BLI also showed high luminescence in control mice compared to [pIC] PEI -treated animals (Fig. 7D) .
In vivo delivery of [pIC] using in vivo
Taken together, these results demonstrate that [pIC] PEI treatment significantly reduced tumor burden in a quasi-orthotopic pancreatic tumor model.
Discussion
Pancreatic cancer remains one of the most difficult cancers to treat effectively. Rapid progression of the disease and diagnosis only after the primary tumor has metastasized are factors contributing to the failure of current approaches to mitigate this disease. Moreover, the lack of noteworthy benefits of current treatment modalities highlights the need for innovative approaches to combat this invariably lethal neoplasm. We presently demonstrate that delivery of 
significantly impacts on therapeutic outcome of cancer patients (26) . [pIC] has been used for decades as a synthetic dsRNA mimic to enhance the immune system in an IFN-dependent manner (25) 
Interestingly, [pIC]
PEI also displayed efficient anti-tumor activity in animals with defective NK, T, or B cell signaling (25, 26) .
[pIC] induces death in a panel of human cancer cell lines, however, it is only in the last few years that receptors for pIC recognition (MDA-5, TLR3 and PKR) have been discovered (27) . induced an IFN-independent pro-apoptotic signaling pathway that was activated by RIG-I and MDA-5 in normal cells as well as in melanoma cells, which led to apoptosis only in melanoma cells (27) . Interestingly, primary cells were less susceptible due to an intact Bcl-xL pathway, did not provide resistance to apoptosis. AKT can phosphorylate XIAP at serine 87 in vitro and in vivo and can also interact with XIAP (33). The XIAP phosphorylation at serine 87 by AKT inhibits its autoubiquitination and ubiquitination functions promoting resistance to cisplatininduced XIAP degradation, caspase-3 activation, and apoptosis (33, 44, 45) . AKT, also known as protein kinase B, is a serine/threonine kinase involved in regulation of cell proliferation, survival/apoptosis, angiogenesis, metabolism, and protein synthesis (46) . AKT plays a seminal role in various cancers (47) (48) (49) (50) (51) (52) (53) PEI treatment of PDAC decreased PKC-ε, which was shown previously to act in a positive feedback loop with AKT (35) . We plan to extend this interesting observation in future studies.
In summary, we demonstrate that cytosolic delivery of [pIC] using PEI in PDAC results in AKT-XIAP-mediated apoptosis in vitro and in vivo.
[pIC] PEI displayed strong antitumor activity in immunodeficient mice, using both human pancreatic tumor xenograft and quasiorthotopic models, demonstrating that an intact immune system is not mandatory for anticancer activity, supporting previous studies in melanoma (25, 27) and breast cancer (26) . Apoptosis is sequentially triggered by inhibition of AKT activation followed by XIAP degradation in 
